Last reviewed · How we verify

MK0966 / Duration of Treatment: 1 Days

Merck Sharp & Dohme LLC · Phase 3 active Small molecule

MK0966 / Duration of Treatment: 1 Days is a COX-2 selective inhibitor (coxib) Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Acute pain, Rheumatoid arthritis, Osteoarthritis.

MK0966 is a selective COX-2 inhibitor that reduces prostaglandin production to decrease inflammation and pain.

MK0966 is a selective COX-2 inhibitor that reduces prostaglandin production to decrease inflammation and pain. Used for Acute pain, Rheumatoid arthritis, Osteoarthritis.

At a glance

Generic nameMK0966 / Duration of Treatment: 1 Days
SponsorMerck Sharp & Dohme LLC
Drug classCOX-2 selective inhibitor (coxib)
TargetCOX-2 (Cyclooxygenase-2)
ModalitySmall molecule
Therapeutic areaRheumatology / Pain Management
PhasePhase 3

Mechanism of action

MK0966 (etoricoxib) selectively inhibits cyclooxygenase-2 (COX-2), an enzyme responsible for producing pro-inflammatory prostaglandins. By blocking COX-2 while sparing COX-1, the drug reduces inflammation and pain with potentially lower gastrointestinal toxicity compared to non-selective NSAIDs. The short 1-day treatment duration suggests acute pain or inflammatory indication.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about MK0966 / Duration of Treatment: 1 Days

What is MK0966 / Duration of Treatment: 1 Days?

MK0966 / Duration of Treatment: 1 Days is a COX-2 selective inhibitor (coxib) drug developed by Merck Sharp & Dohme LLC, indicated for Acute pain, Rheumatoid arthritis, Osteoarthritis.

How does MK0966 / Duration of Treatment: 1 Days work?

MK0966 is a selective COX-2 inhibitor that reduces prostaglandin production to decrease inflammation and pain.

What is MK0966 / Duration of Treatment: 1 Days used for?

MK0966 / Duration of Treatment: 1 Days is indicated for Acute pain, Rheumatoid arthritis, Osteoarthritis, Ankylosing spondylitis.

Who makes MK0966 / Duration of Treatment: 1 Days?

MK0966 / Duration of Treatment: 1 Days is developed by Merck Sharp & Dohme LLC (see full Merck Sharp & Dohme LLC pipeline at /company/merck).

What drug class is MK0966 / Duration of Treatment: 1 Days in?

MK0966 / Duration of Treatment: 1 Days belongs to the COX-2 selective inhibitor (coxib) class. See all COX-2 selective inhibitor (coxib) drugs at /class/cox-2-selective-inhibitor-coxib.

What development phase is MK0966 / Duration of Treatment: 1 Days in?

MK0966 / Duration of Treatment: 1 Days is in Phase 3.

What are the side effects of MK0966 / Duration of Treatment: 1 Days?

Common side effects of MK0966 / Duration of Treatment: 1 Days include Hypertension, Edema, Dyspepsia, Headache, Cardiovascular events.

What does MK0966 / Duration of Treatment: 1 Days target?

MK0966 / Duration of Treatment: 1 Days targets COX-2 (Cyclooxygenase-2) and is a COX-2 selective inhibitor (coxib).

Related